Nerisona (Diflucortolone Valerate)

Diflucortolone Valerate, the active ingredient in Nerisona, is a corticosteroid presented as a topical formulation for topical use. It is employed to reduce inflammation and relieve symptoms in skin disorders such as psoriasis, eczema and dermatitis. It is indicated for adult patients with moderate to severe inflammatory skin conditions where topical therapy is appropriate.

GNH USA supplies Nerisona as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union regulatory standards and is distributed under a prescription‑only status.

Diflucortolone Valerate is used in dermatology to manage inflammatory skin disorders.

- Psoriasis: reduces scaling, erythema and itching associated with plaque lesions. - Eczema: alleviates inflammation and pruritus in atopic dermatitis. - Dermatitis: controls acute flare‑ups of contact or seborrheic dermatitis.

Topical application of Diflucortolone Valerate may be associated with local and systemic adverse reactions.

Common Side Effects: - Burning sensation: transient stinging at the application site, usually brief. - Pruritus: mild itching that may accompany irritation. - Dryness: skin can become dry or flaky. - Erythema: mild redness of the treated area. - Hypertrichosis: excessive hair growth may appear on the treated region. - Contact dermatitis: allergic reaction to the formulation.

Serious or Rare Side Effects: - Skin atrophy: thinning of skin with prolonged use, increasing fragility. - Telangiectasia: small visible blood vessels may develop on thin skin. - Systemic cortisol suppression: possible adrenal axis inhibition when large areas are treated extensively.

When using Nerisona, consider the following precautions.

- Assess severity: use only for moderate to severe inflammatory skin conditions when topical therapy is indicated. - Limit duration: avoid continuous use beyond two weeks unless directed by a physician. - Avoid occlusion: do not cover treated area with airtight dressings unless prescribed. - Monitor for infection: discontinue if secondary bacterial or fungal infection develops. - Pregnancy and lactation: consult healthcare provider before use as safety data are limited. - Store below 25°C: keep in the original container, protect from moisture and light.

Diflucortolone Valerate may interact with other medicines.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent systemic use may increase risk of adrenal suppression. - Antifungal azoles: may enhance local steroid absorption, raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Topical NSAIDs: may increase skin irritation. - Antiviral creams: potential for reduced efficacy of either agent. - Phototherapy: may augment skin thinning when combined with potent topical steroids.